Search:
Browse
Collection All
bullet
bullet
bullet
bullet
bullet
bullet
Listed communities
bullet
bullet
bullet
bullet
bullet
bullet
bullet
bullet

Anglia Ruskin Research Online > Faculty of Health, Social Care and Education (FHSC&E)  > Faculty of Health, Social Care and Education (FHSC&E) for research post September 2011 > RNA biomarkers in colorectal cancer

Please use this identifier to cite or link to this item: http://hdl.handle.net/10540/251415
    Del.icio.us     LinkedIn     Citeulike     Connotea     Facebook     Stumble it!


Title: RNA biomarkers in colorectal cancer
Authors: Bustin, Stephen A.
Murphy, Jamie
Affiliation: Anglia Ruskin University
Division of Colon and Rectal Surgery, Mayo Clinic, AZ, USA
Reference: Bustin, S.A. and Murphy, J., 2012. RNA biomarkers in colorectal cancer. Methods, article in press.
Publisher: Elsevier
Journal: Methods
Issue Date: 15-Oct-2012
URI: http://hdl.handle.net/10540/251415
DOI: 10.1016/j.ymeth.2012.10.003
PubMed ID: 23079397
Additional Links: http://www.sciencedirect.com/science/article/pii/S1046202312002587
Abstract: Colorectal cancer (CRC) develops and progresses through a systematic selection for (epi) genetic alterations that drive the transformation from normal colon epithelium to adenocarcinoma. These changes affect both noncoding RNAs and mRNAs and so define the clinical behaviour of cancer cells within a distinctive host genetic and environmental context. Although earlier diagnosis and more effective treatment modalities have decreased mortality from CRC, prognostic stratification and adjuvant therapy selection after surgery remain dependent on broad descriptive classifications, opportune histological markers of poor prognosis and chemotherapy efficacy data derived from diverse CRC populations. Crucially, there is significant inter- and intra-individual variability in response to, and tolerance of, chemotherapy treatments. These limitations explain the small clinical benefit of new agents studied in contemporary phase III trials. Molecular assays have the potential to address these constraints and there has been intense interest in the identification of clinically relevant molecular biomarkers. These must be easy to obtain and quantify and ideally represent steps in well-understood carcinogenic pathways or host-response mechanisms. Although some biomarkers can provide broad prognostic information based on CRC subtype (e.g. MSI status) or can somewhat predict response to targeted therapies (e.g. KRAS), no RNA-based biomarkers have entered routine clinical practice. This is due, in part, to the genetic heterogeneity of both patients and CRC. In addition, serious underlying issues with regards to study design, poor technical protocols, inadequate quality controls and inappropriate data analysis prevent successful translation of research results. Consequently, the identification of clinically relevant panels of biomarkers will depend not just on further advances in our understanding of CRC biology, but will need to be coupled with appropriate study designs and more suitable, standardised and transparent techniques.
Type: Article
Language: en
Keywords: metastasis
prognosis
diagnosis
response prediction
staging
miRNA
circulating tumour cells
ISSN: 1095-9130
Appears in Collections: Faculty of Health, Social Care and Education (FHSC&E) for research post September 2011

Files in This Item:
File Description Size Format View/Open
methods 2012.pdfUncorrected proof of article text 1127KbAdobe PDFThumbnail
View/Open

Related articles on PubMed
bullet
Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN
2007
bullet
Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, Dillon W, Warach S, Broderick J, Tilley B, Sacks D, Technology Assessment Committee of the American Society of Interventional and Therapeutic Neuroradiology, Technology Assessment Committee of the Society of Interventional Radiology
2003 Aug
bullet

Chung M, Moorthy D, Hadar N, Salvi P, Iovin RC, Lau J
2012 Oct
bullet
bullet
See all 81 articles

All Items in ARRO are protected by copyright, with all rights reserved, unless otherwise indicated.